JP2015502400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015502400A5 JP2015502400A5 JP2014548324A JP2014548324A JP2015502400A5 JP 2015502400 A5 JP2015502400 A5 JP 2015502400A5 JP 2014548324 A JP2014548324 A JP 2014548324A JP 2014548324 A JP2014548324 A JP 2014548324A JP 2015502400 A5 JP2015502400 A5 JP 2015502400A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- liposome
- glycero
- chlorite
- phosphocholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 89
- 239000002502 liposome Substances 0.000 claims 52
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 claims 32
- 150000002632 lipids Chemical class 0.000 claims 30
- 238000000034 method Methods 0.000 claims 27
- 229910001919 chlorite Inorganic materials 0.000 claims 23
- 229910052619 chlorite group Inorganic materials 0.000 claims 23
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 239000000232 Lipid Bilayer Substances 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 150000002500 ions Chemical class 0.000 claims 4
- 230000002776 aggregation Effects 0.000 claims 3
- 238000004220 aggregation Methods 0.000 claims 3
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 claims 3
- 230000001613 neoplastic effect Effects 0.000 claims 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- DSNRWDQKZIEDDB-SQYFZQSCSA-N 1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-SQYFZQSCSA-N 0.000 claims 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 2
- TYAQXZHDAGZOEO-KXQOOQHDSA-N 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCC TYAQXZHDAGZOEO-KXQOOQHDSA-N 0.000 claims 2
- UIXXHROAQSBBOV-PSXMRANNSA-N 1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC UIXXHROAQSBBOV-PSXMRANNSA-N 0.000 claims 2
- MZWGYEJOZNRLQE-KXQOOQHDSA-N 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC MZWGYEJOZNRLQE-KXQOOQHDSA-N 0.000 claims 2
- YKIOPDIXYAUOFN-UHFFFAOYSA-N 2,3-di(icosanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC YKIOPDIXYAUOFN-UHFFFAOYSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 235000010469 Glycine max Nutrition 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 101001000212 Rattus norvegicus Decorin Proteins 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- RZBMBMLIIRIAMH-LDLOPFEMSA-N [(2R)-2,3-dihydroxypropyl] 2-[di(octadecanoyl)amino]ethyl hydrogen phosphate Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)N(CCOP(OC[C@@H](CO)O)(=O)O)C(CCCCCCCCCCCCCCCCC)=O RZBMBMLIIRIAMH-LDLOPFEMSA-N 0.000 claims 2
- 201000009961 allergic asthma Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000008344 egg yolk phospholipid Substances 0.000 claims 2
- 229940068998 egg yolk phospholipid Drugs 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000003408 sphingolipids Chemical class 0.000 claims 2
- HRTBOPUWPUXROO-VCZQVZGSSA-N (2-{[(2r)-2,3-bis(docosanoyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC HRTBOPUWPUXROO-VCZQVZGSSA-N 0.000 claims 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- ATHVAWFAEPLPPQ-VRDBWYNSSA-N 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC ATHVAWFAEPLPPQ-VRDBWYNSSA-N 0.000 claims 1
- BYSIMVBIJVBVPA-RRHRGVEJSA-N 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC BYSIMVBIJVBVPA-RRHRGVEJSA-N 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 101000823778 Homo sapiens Y-box-binding protein 2 Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- SXZWBNWTCVLZJN-NMIJJABPSA-N N-tricosanoylsphing-4-enine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC SXZWBNWTCVLZJN-NMIJJABPSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- FVJZSBGHRPJMMA-DHPKCYQYSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-DHPKCYQYSA-N 0.000 claims 1
- BPHQZTVXXXJVHI-IADGFXSZSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-tetradecanoyloxypropyl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-IADGFXSZSA-N 0.000 claims 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 230000007012 clinical effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000007857 degradation product Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000004043 dyeing Methods 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 150000002190 fatty acyls Chemical group 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- LLCSXHMJULHSJN-LWOQYNTDSA-N sn-glycero-3-phosphoglycerol Chemical compound OCC(O)COP(O)(=O)OC[C@H](O)CO LLCSXHMJULHSJN-LWOQYNTDSA-N 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- YNQYZBDRJZVSJE-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl 2,3-di(octadecanoyloxy)propyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC YNQYZBDRJZVSJE-UHFFFAOYSA-M 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 238000013517 stratification Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579326P | 2011-12-22 | 2011-12-22 | |
| US61/579,326 | 2011-12-22 | ||
| PCT/IB2012/057645 WO2013093891A1 (en) | 2011-12-22 | 2012-12-21 | Liposomal chlorite or chlorate compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015502400A JP2015502400A (ja) | 2015-01-22 |
| JP2015502400A5 true JP2015502400A5 (OSRAM) | 2015-11-05 |
Family
ID=47630448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548324A Pending JP2015502400A (ja) | 2011-12-22 | 2012-12-21 | リポソームの亜塩素酸塩または塩素酸塩組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130177629A1 (OSRAM) |
| EP (1) | EP2793860A1 (OSRAM) |
| JP (1) | JP2015502400A (OSRAM) |
| CN (1) | CN104125826A (OSRAM) |
| AU (1) | AU2012297589C1 (OSRAM) |
| BR (1) | BR112014015333A8 (OSRAM) |
| CA (1) | CA2857604A1 (OSRAM) |
| IN (1) | IN2014DN05866A (OSRAM) |
| MX (1) | MX2014007664A (OSRAM) |
| RU (1) | RU2014130080A (OSRAM) |
| WO (1) | WO2013093891A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5324223B2 (ja) | 2005-12-08 | 2013-10-23 | トランセイブ， インク． | 肺感染症を治療する抗感染薬の脂質ベースの組成物及びその使用法 |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| WO2014037927A1 (en) * | 2012-09-10 | 2014-03-13 | Nuvo Research Gmbh | Chlorate compositions and use of chlorate for treating radiation exposure |
| MX2015006681A (es) | 2012-11-29 | 2016-04-06 | Insmed Inc | Formulaciones de vancomicina estabilizadas. |
| US9603799B2 (en) | 2013-03-15 | 2017-03-28 | Htd Biosystems Inc. | Liposomal vaccine adjuvants and methods of making and using same |
| US20140271815A1 (en) * | 2013-03-15 | 2014-09-18 | Aryo Sorayya | Heat-and freeze-stable vaccines and methods of making and using same |
| SMT202000516T1 (it) | 2014-05-15 | 2020-11-10 | Insmed Inc | Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari |
| US11813234B2 (en) * | 2015-08-20 | 2023-11-14 | Oxo Translational Science Gmbh | Use of chlorite to treat red blood cell diseases and indications mediated thereby |
| EP3402464A4 (en) * | 2016-01-04 | 2019-10-09 | Academia Sinica | Esterification / slip-based method for liposome loading |
| US20190142864A1 (en) * | 2017-10-11 | 2019-05-16 | California Institute Of Technology | Methods and systems, for interfering with viability of bacteria and related antimicrobials and compositions |
| WO2019160519A2 (en) * | 2018-02-15 | 2019-08-22 | Yeditepe Universitesi | Exosome isolation method by two phase fluid system |
| WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| WO2019213398A1 (en) | 2018-05-02 | 2019-11-07 | Insmed Incorporated | Methods for the manufacture of liposomal drug formulations |
| CN110563829B (zh) * | 2019-09-17 | 2021-03-26 | 中国人民解放军国防科技大学 | 用于调控脂质体囊泡行为、功能的反光蛋白体系及其应用 |
| CN112716973A (zh) * | 2019-10-28 | 2021-04-30 | 卢序 | 一种降低细胞还原应激的氧化剂的用途 |
| TR202012260A2 (tr) * | 2020-08-05 | 2020-10-21 | Emin Zuemruetdal | Oral kullanim i̇çi̇n potasyum hi̇droksi̇t/sodyum hi̇droksi̇t solüsyonu |
| WO2023225125A1 (en) * | 2022-05-19 | 2023-11-23 | Neuvivo, Inc. | Biomarkers for neurogenerative disease |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4356167A (en) | 1978-01-27 | 1982-10-26 | Sandoz, Inc. | Liposome drug delivery systems |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4241046A (en) | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| DE3213389A1 (de) | 1982-04-10 | 1983-10-20 | Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne | Stabilisierter aktivierter sauerstoff und arzneimittel, die diesen stabilisierten aktivierten sauerstoff enthalten |
| US4551288A (en) | 1982-08-16 | 1985-11-05 | Sandoz, Inc. | Processes for the preparation of liposome drug delivery systems |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4574084A (en) | 1983-02-25 | 1986-03-04 | Peter Berger | Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof |
| US5008050A (en) | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4663161A (en) | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
| DE3515745A1 (de) | 1985-05-02 | 1986-11-06 | Oxo Chemie GmbH, 6900 Heidelberg | Waessrige chloritmatrix-loesung |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| JPH0751496B2 (ja) | 1986-04-02 | 1995-06-05 | 武田薬品工業株式会社 | リポソ−ムの製造法 |
| DE3625867C2 (de) | 1986-07-31 | 1995-10-19 | Elstner Erich F Prof Dr | Verwendung von Tetrachlordecaoxid in der Ophthalmologie |
| US4752425A (en) | 1986-09-18 | 1988-06-21 | Liposome Technology, Inc. | High-encapsulation liposome processing method |
| US4781871A (en) | 1986-09-18 | 1988-11-01 | Liposome Technology, Inc. | High-concentration liposome processing method |
| US5049388A (en) | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
| EP0414663A4 (en) | 1987-04-16 | 1991-07-17 | The Liposome Company, Inc. | Liposome continuous size reduction method and apparatus |
| US5049390A (en) | 1987-09-02 | 1991-09-17 | Allergy Immuno Technologies, Inc. | Liposome containing immunotherapy agents for treating IgE mediated allergies |
| US4851222A (en) | 1988-01-27 | 1989-07-25 | Oxo Chemie Gmbh | Method of promoting regeneration of bone marrow |
| US5269979A (en) | 1988-06-08 | 1993-12-14 | Fountain Pharmaceuticals, Inc. | Method for making solvent dilution microcarriers |
| US4927637A (en) | 1989-01-17 | 1990-05-22 | Liposome Technology, Inc. | Liposome extrusion method |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| US5190822A (en) | 1990-04-20 | 1993-03-02 | Fuji Photo Film Co., Ltd. | Surface-modifiable liposome and process for producing surface-modified liposome |
| US5206027A (en) | 1990-09-13 | 1993-04-27 | Fuji Photo Film Co., Ltd. | Amphipathic compound and liposome comprising the same |
| WO1992007959A1 (en) | 1990-11-05 | 1992-05-14 | Biowhittaker Inc. | Homogeneous membrane lytic immunoassay method utilizing contact sensitive liposome formulations |
| US5498420A (en) | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
| US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
| JPH06206825A (ja) | 1992-12-11 | 1994-07-26 | Nippon Rooshiyon Kk | 白癬菌、湿疹等による皮膚病の治療剤及び 皮膚殺菌活性化剤 |
| DE59406065D1 (de) | 1993-03-24 | 1998-07-02 | Ciba Geigy Ag | Verfahren zur Herstellung einer Liposomendispersion im Hochdruckbereich |
| EP0734438A4 (en) | 1993-12-17 | 1998-12-23 | Spinal Cord Society | METHOD FOR INDUCING DNA SYNTHESIS IN NEURONES |
| US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US6110666A (en) | 1994-06-09 | 2000-08-29 | Medical Research Council | Locus control subregions conferring integration-site independent transgene expression abstract of the disclosure |
| US5786214A (en) | 1994-12-15 | 1998-07-28 | Spinal Cord Society | pH-sensitive immunoliposomes and method of gene delivery to the mammalian central nervous system |
| US5780052A (en) | 1995-04-24 | 1998-07-14 | Northeastern University | Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell |
| JP3735921B2 (ja) | 1996-02-07 | 2006-01-18 | 三菱ウェルファーマ株式会社 | ＧＰＩｂ・脂質複合体およびその用途 |
| US5877222A (en) | 1996-07-19 | 1999-03-02 | The Regents Of The University Of California | Method for treating aids-associated dementia |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US6524613B1 (en) | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
| WO1999017787A2 (en) | 1997-10-06 | 1999-04-15 | Oxo Chemie Ag | Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response |
| US6749863B1 (en) | 1997-11-19 | 2004-06-15 | Georgetown University | Targeted liposome gene delivery |
| DE69830249T2 (de) | 1997-11-19 | 2006-05-04 | Georgetown University | Zielgerichtete liposomen zur verabreichung von genen |
| AU2669599A (en) | 1998-02-12 | 1999-08-30 | Regents Of The University Of California, The | Compositions for receptor/liposome mediated transfection and methods of using same |
| US6077502A (en) | 1998-02-27 | 2000-06-20 | The Procter & Gamble Company | Oral care compositions comprising chlorite and methods |
| US6132702A (en) | 1998-02-27 | 2000-10-17 | The Procter & Gamble Company | Oral care compositions comprising chlorite and methods |
| US6251372B1 (en) | 1998-02-27 | 2001-06-26 | The Procter & Gamble Company | Oral care compositions comprising chlorite and methods |
| US6350438B1 (en) | 1998-02-27 | 2002-02-26 | The Procter & Gamble Company | Oral care compositions comprising chlorite and methods |
| US6245427B1 (en) | 1998-07-06 | 2001-06-12 | DüZGüNES NEJAT | Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles |
| AU6416999A (en) | 1998-10-08 | 2000-04-26 | Hampar L. Karagoezian | Synergistic antimicrobial, dermatological and ophthalmic preparations containingchlorite and hydrogen peroxide |
| JP4727816B2 (ja) * | 1998-10-08 | 2011-07-20 | エル． カラジョージアン、ハンパー | 亜塩素酸塩と過酸化水素とを含有する共同作用抗菌性皮膚科・眼科製剤 |
| JP2001002592A (ja) | 1999-06-18 | 2001-01-09 | Dai Ichi Seiyaku Co Ltd | 遺伝子導入用組成物 |
| CA2382293A1 (en) | 1999-08-18 | 2001-02-22 | Oxo Chemie Ag | Chemically-stabilized chlorite solutions for treating cancer and other diseases |
| WO2001017030A1 (en) | 1999-08-27 | 2001-03-08 | Macronix America, Inc. | Non-volatile memory structure for twin-bit storage and methods of making same |
| US20070104798A1 (en) * | 1999-10-04 | 2007-05-10 | S.K. Pharmaceuticals, Inc. | Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide |
| CA2391606A1 (en) | 1999-11-24 | 2001-05-31 | The Liposome Company, Inc. | Modular targeted liposomal delivery system |
| EP1246606A2 (en) | 1999-12-30 | 2002-10-09 | Judith K. Gwathmey | Iron chelator delivery system |
| US6530944B2 (en) | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| AU2002346446A1 (en) | 2001-11-20 | 2003-06-10 | Baylor College Of Medicine | Methods and compositions in checkpoint signaling |
| US20030220284A1 (en) | 2002-02-22 | 2003-11-27 | Patricia Yotnda | Delivery of adenoviral DNA in a liposomal formulation for treatment of disease |
| KR20030072766A (ko) | 2002-03-06 | 2003-09-19 | (주)인터커머스 | 구취 억제능이 우수한 구강 위생용 조성물 및 그의제조방법 |
| US20030228285A1 (en) | 2002-05-03 | 2003-12-11 | Mien-Chie Hung | Bipartite T-cell factor (Tcf)-responsive promoter |
| US20040022842A1 (en) | 2002-06-03 | 2004-02-05 | Mebiopharm Co., Ltd. | Liposome preparations containing oxaliplatin |
| JP3415131B1 (ja) | 2002-06-03 | 2003-06-09 | メビオファーム株式会社 | リポソーム製剤 |
| US7105183B2 (en) | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| US8765808B2 (en) * | 2005-03-23 | 2014-07-01 | Chs Pharma, Inc. | Treatment or prevention of cancer and precancerous disorders |
| WO2007009245A1 (en) | 2005-07-21 | 2007-01-25 | Nuvo Research Inc. | Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment. |
| AU2006331497B2 (en) * | 2005-12-22 | 2013-07-04 | Neuraltus Pharmaceuticals, Inc. | Chlorite formulations, and methods of preparation and use thereof |
| EP1971426A1 (de) | 2006-01-11 | 2008-09-24 | P & W Invest Vermögensverwaltungsgesellschaft mbH | Hüllenmembran zur abgabe eines eingeschlossenen wirkstoffs, ein verfahren zur herstellung sowie deren verwendung |
| US8252343B2 (en) | 2007-06-01 | 2012-08-28 | Nuvo Research Ag | Use of WF10 for treating allergic asthma, allergic rhinitis and atopic dermatitis |
| US20110052655A1 (en) | 2007-08-08 | 2011-03-03 | Wilson Kurt Whitekettle | Methods and vesicles for controlling protozoa |
| US8283333B2 (en) * | 2009-07-01 | 2012-10-09 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
| US20110177147A1 (en) | 2010-01-21 | 2011-07-21 | General Electric Company | Stable biocidal delivery systems |
-
2012
- 2012-12-21 EP EP12820937.6A patent/EP2793860A1/en not_active Withdrawn
- 2012-12-21 AU AU2012297589A patent/AU2012297589C1/en not_active Ceased
- 2012-12-21 CN CN201280070434.8A patent/CN104125826A/zh active Pending
- 2012-12-21 WO PCT/IB2012/057645 patent/WO2013093891A1/en not_active Ceased
- 2012-12-21 RU RU2014130080A patent/RU2014130080A/ru not_active Application Discontinuation
- 2012-12-21 BR BR112014015333A patent/BR112014015333A8/pt not_active IP Right Cessation
- 2012-12-21 JP JP2014548324A patent/JP2015502400A/ja active Pending
- 2012-12-21 CA CA2857604A patent/CA2857604A1/en not_active Abandoned
- 2012-12-21 US US13/724,963 patent/US20130177629A1/en not_active Abandoned
- 2012-12-21 IN IN5866DEN2014 patent/IN2014DN05866A/en unknown
- 2012-12-21 MX MX2014007664A patent/MX2014007664A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014130080A (ru) | Липосомальные композиции хлоритов или хлоратов | |
| JP6449848B2 (ja) | 水性及び非水性区画の両方におけるリポソーム組成物による制御薬物放出プロファイルの操作 | |
| CN102223878A (zh) | 包含鞘磷脂的脂质体系统 | |
| JP2020528432A (ja) | 弱酸性薬物を含むリポソーム組成物およびその使用 | |
| JP2015515992A5 (OSRAM) | ||
| TW201841622A (zh) | 熱塑性奈米粒子及其製法 | |
| KR20200044902A (ko) | 서방형 마취제 조성물 및 이의 제조 방법 | |
| CN115243677A (zh) | 用于递送治疗剂的生物可降解药物洗脱栓塞颗粒 | |
| US20260108534A1 (en) | Liposomal formulations of bcl inhibitors | |
| Maheswaran et al. | Liposomal drug delivery systems—a review | |
| Hu et al. | Liposomes in drug delivery: status and advances | |
| JP6533297B2 (ja) | 表皮成長因子とリポソームのハイブリッド型多層ナノ構造体及びその製造方法 | |
| CN107708670A (zh) | 磷脂包衣的治疗剂纳米颗粒和有关的方法 | |
| JP2008285459A (ja) | リポソーム製剤の製造方法 | |
| Sanarova et al. | Liposome drug delivery | |
| KR20070011331A (ko) | 리포솜 제제 | |
| EP2398463A1 (en) | A method for amphiphilic drug loading in liposomes by ion gradient | |
| CN105517538A (zh) | 镁-脂质体 | |
| CN109077998A (zh) | 沙美特罗脂质复合物及其制备方法 | |
| JP2000302685A (ja) | 抗腫瘍薬含有リポソーム製剤 | |
| RU2791481C2 (ru) | Анестетические композиции с замедленным высвобождением и способы их получения | |
| C Santos et al. | Thermolabile liposomes: a controlled release delivery tool in diagnosis/therapy in experimental pulmonary oedema | |
| JP2022505378A (ja) | 免疫調節剤を含む徐放性医薬組成物およびその使用 | |
| TW202220668A (zh) | 用於疼痛控制之關節內皮質類固醇的藥學組成物 | |
| BR122024008482A2 (pt) | Composições anestésicas de liberação sustentada |